LIRAGLUTIDE
What Is LIRAGLUTIDE?
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a synthetic peptide that shares 97% amino acid sequence identity with native human GLP-1. It works by mimicking the incretin hormone GLP-1, which stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system mechanisms. Primarily approved for treating type 2 diabetes mellitus and obesity, it has also shown potential benefits in reducing cardiovascular risk, sarcopenia, and metabolic syndrome.
LIRAGLUTIDE Research & Studies
01 Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway ▸
Liraglutide demonstrated protective effects against diabetic sarcopenia in rat models, improving muscle health and reducing cellular senescence through the YAP-TAZ pathway, beyond its established glucose-lowering and weight-reducing benefits.
View Study (PubMed)02 Liraglutide prevents high glucose level induced insulinoma cells apoptosis by targeting autophagy ▸
Liraglutide protected pancreatic beta cells from high glucose-induced apoptosis by modulating autophagy pathways, suggesting a mechanism for preserving beta cell function in type 2 diabetes.
View Study (PubMed)03 Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis ▸
Network meta-analysis found liraglutide 1.8mg daily reduced waist circumference by 5.24cm and 1.2mg daily by 4.73cm in type 2 diabetes patients, demonstrating significant effects on abdominal obesity beyond weight loss.
View Study (PubMed)04 Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review ▸
Systematic review of 15 RCTs showed liraglutide consistently reduced total weight, fat mass, and visceral adipose tissue by 12.49-23% compared to placebo, effectively targeting visceral fat associated with cardiometabolic risk.
View Study (PubMed)05 Liraglutide, a glucagon-like peptide-1 analog, inhibits high glucose-induced oxidative stress and apoptosis in neonatal rat cardiomyocytes ▸
Liraglutide protected cardiomyocytes from high glucose-induced damage by reducing oxidative stress and apoptosis, demonstrating cardioprotective effects that may help prevent diabetic cardiomyopathy.
View Study (PubMed)06 Liraglutide and resveratrol alleviated cyclosporin A induced nephrotoxicity in rats through improving antioxidant status, apoptosis and pro-inflammatory markers ▸
Liraglutide demonstrated renoprotective effects by improving kidney function, reducing inflammation, and enhancing antioxidant status in rats with drug-induced nephrotoxicity.
View Study (PubMed)07 Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high-fat diet ▸
Liraglutide reduced body weight gain, food intake, hyperglycemia, and improved glucose tolerance in a dose-dependent manner in a severe metabolic syndrome rat model.
View Study (PubMed)08 Liraglutide-induced autoimmune hepatitis ▸
Case report documented a rare instance of marker-negative autoimmune hepatitis associated with liraglutide therapy, highlighting the importance of monitoring liver function during treatment.
View Study (PubMed)LIRAGLUTIDE User Reviews & Experiences
*Based on large scale analysis of publicly available user experiences
User sentiment regarding liraglutide and GLP-1 agonists is genuinely mixed, with some users reporting significant benefits for weight loss and metabolic health, while others express concerns about long-term dependency, side effects, and the general trend toward pharmaceutical interventions over lifestyle modifications. The discussions show both enthusiasm for the therapeutic potential and caution about unknown long-term consequences.
LIRAGLUTIDE Benefits, Dosage & Side Effects
- Appetite Suppression: Significant reduction in hunger and food cravings, making caloric restriction and intermittent fasting more manageable
- Weight Loss: Consistent reduction in body weight, fat mass, and particularly visceral adipose tissue, with effects ranging from 12-23% reduction in VAT
- Metabolic Improvements: Enhanced glucose control, improved insulin sensitivity, and reduced HbA1c levels in diabetic patients
- Body Composition: Preservation of muscle mass while reducing fat mass, with potential benefits for sarcopenia prevention
- Dose-Dependent Response: Studies show 1.8mg daily produces greater effects than 1.2mg, with visceral fat reduction and waist circumference improvements being dose-related
- Consistent Results: Multiple systematic reviews and RCTs demonstrate reliable weight loss and metabolic improvements compared to placebo across diverse populations
- Beyond Glycemic Control: Benefits extend to cardiovascular protection, neuroprotection, anti-inflammatory effects, and potential cognitive benefits
- Individual Variation: Effectiveness varies significantly between individuals, with some experiencing dramatic benefits while others see minimal response
- Type 2 Diabetes: Standard dosing starts at 0.6mg daily, titrated up to 1.2-1.8mg daily based on tolerance and response
- Weight Management: Typical dosing for obesity is 3.0mg daily (marketed as higher-dose formulation), started gradually to minimize GI side effects
- Subcutaneous Administration: Once-daily injection, typically in abdomen, thigh, or upper arm, with gradual dose escalation over 4-8 weeks
- Off-Label Intermittent Use: Some users experiment with intermittent dosing (e.g., only on fasting days) though this lacks clinical evidence
- Gastrointestinal Effects: Nausea, vomiting, diarrhea, and constipation are most common, particularly during dose escalation, typically improving over time
- Rare Hepatotoxicity: Case reports document autoimmune hepatitis and liver enzyme elevation, requiring monitoring of liver function
- Dependency Concerns: Users report difficulty maintaining weight loss after discontinuation, with appetite returning to baseline or higher
- Long-Term Unknowns: Limited data on effects of multi-year use, with concerns about pancreatic health, thyroid effects, and unknown metabolic adaptations
- Prescription Required: Liraglutide is available only by prescription in most countries, approved for type 2 diabetes (Victoza) and obesity (Saxenda)
- High Cost: Significant expense even with insurance coverage, with many users reporting affordability issues and insurance companies often not covering weight loss indications
- Growing Use: Increasing popularity has led to supply shortages and expanded off-label use, particularly among biohackers seeking metabolic optimization
Community Reviews
Share your experience with LIRAGLUTIDE and help others make informed decisions.
Write a Review
Sign in to leave a review